Rigel Pharmaceuticals Inc RIGL:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 03/08/21 EST
3.72quote price arrow up+0.05 (+1.36%)
Volume
3,832
Close
3.67quote price arrow down-0.17 (-4.43%)
Volume
3,655,065
52 week range
1.23 - 5.50

...

Loading . . .

KEY STATS

  • Open3.93
  • Day High3.94
  • Day Low3.52
  • Prev Close3.67
  • 52 Week High5.50
  • 52 Week High Date02/18/21
  • 52 Week Low1.23
  • 52 Week Low Date03/19/20
  • Market Cap624.05M
  • Shares Out170.04M
  • 10 Day Average Volume5.29M
  • Dividend-
  • Dividend Yield-
  • Beta1.55
  • 1 Year % Change65.32

RATIOS/PROFITABILITY

  • EPS (TTM)-0.18
  • P/E (TTM)-20.85
  • Fwd P/E (NTM)-73.40
  • EBITDA (MRQ)-28.267M
  • ROE (MRQ)-67.72%
  • Revenue (MRQ)108.62M
  • Gross Margin (MRQ)99.18%
  • Net Margin (MRQ)-27.38%
  • Debt To Equity (MRQ)58.23%

EVENTS

  • Earnings Date05/05/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Rigel Pharmaceuticals Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult...
Raul Rodriguez
President
Dean Schorno CPA
Chief Financial Officer
Dolly Vance
Executive Vice President
Wolfgang Dummer M.D. Ph.D.
Executive Vice President
David Santos
Executive Vice President
Address
1180 Veterans Blvd
South San Francisco, CA
94080-1985
United States